Thông tin thuốc gốc
Chỉ định và Liều dùng
Hyperactivity disorders
Child: 6-17 yr As immediate-release preparation: Initially, 5 mg once or bid. May increase to 5-10 mg at wkly intervals, if necessary. Max: 60 mg daily in divided doses. Consider a later dose in the evening if the effect wears off. Discontinue periodically to re-evaluate or if there is no improvement w/in 1 mth. Modified-release forms: Dose varies depending on brand.

Adult: 20-30 mg daily in divided doses. Effective dose: 10-60 mg daily.

Hyperactivity disorders
Child: 6-17 yr As patch delivering 1.1-3.3 mg/hr: Apply to hip area once daily in the morning 2 hr before an effect is needed and remove after 9 hr. Start w/ the lowest patch strength, then titrate according to response. Increase at wkly intervals as needed. Max: 3.3 mg/hr (at wk 4).
Cách dùng
tab: Should be taken on an empty stomach. Take 30-45 min before meals.
sustained release tab: May be taken with or without food. Swallow whole, do not divide/chew/crush.
Chống chỉ định
History of marked anxiety, tension, agitation; glaucoma; hyperthyroidism; anorexia; phaeochromocytoma; tics or family history or diagnosis of Tourette's syndrome. Pre-existing CV disorders (e.g. severe HTN, heart failure, angina, MI, arrhythmia); aneurysm; vascular abnormalities. Concomitant or w/in 14 days of MAOI use.
Thận trọng
Patient w/ history of seizure disorder, alcohol or drug abuse. HTN and other CV disorders that might be exacerbated by increases in BP or heart rate; pre-existing psychosis or bipolar disorder. Childn. Pregnancy and lactation.
Tác dụng không mong muốn
Abdominal pain, aggression, alopecia, anorexia, arrhythmias, arthralgia, asthenia, changes in BP, cough, depression, diarrhoea, dizziness, dry mouth, dyspepsia, fever, growth restriction, headache, insomnia, irritability, movement disorders, nasopharyngitis, nausea, nervousness, palpitation, pruritus, rash, wt loss, tachycardia, tics, vomiting, confusion, abnormal dreams, constipations, dyspnoea, epistaxis, muscle cramps, suicidal ideation, urinary frequency. Rarely, angina, sweating, visual disturbances, cerebral arteritis, blood disorders, angle-closure glaucoma, seizures, tolerance, MI. Transdermal: Insomnia, decreased appetite; nausea; tic, emotional instability; vomiting, anorexia; nasal congestion, nasopharyngitis; wt loss.
PO/Transdermal: Z (Associated with small increased risk of cardiac malformations. Consider foetal ECG if methylphenidate is required in first trimester.)
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, drowsiness and visual disturbances, if affected, do not drive or operate machinery. Avoid exposure of application site to any direct external heat source (TTS).
Chỉ số theo dõi
Monitor pulse, BP, psychiatric symptoms, appetite, wt and height prior to initiation, every dose adjustment and at least 6 mthly. Periodic CBC w/ differential and platelet count during prolonged therapy. Monitor for blisterings or oedema which does not improve w/in 48 hr of patch removal, or spreads beyond patch site.
Quá liều
Symptoms: Vomiting, tremor, agitation, muscle twitching, hyperpyrexia, hallucinations, euphoria, confusions, delirium, sweating, flushing, headache, HTN, dryness of mucous membranes, tachycardia, mydriasis, palpitations. Management: Symptomatic and supportive treatment.
Tương tác
May reduce effects of antihypertensive agents. May increase serum levels of phenytoin, TCAs. Risk of sudden BP increase during surgery w/ halogenated anaesth. May enhance the adverse/toxic effects of clonidine.
Potentially Fatal: Increased risk of hypertensive crisis w/ MAOIs.
Tương tác với thức ăn
Food may increase oral absorption of immediate-release preparations. Alcohol may exacerbate adverse CNS effects.
Ảnh hưởng đến kết quả xét nghiệm
False-positive result for amphetamine urine detection test.
Tác dụng
Description: Methylphenidate is a mild CNS stimulant which blocks the reuptake of norepinephrine and dopamine into presynaptic neurons. It also stimulates the cerebral cortex and subcortical structures causing increased sympathomimetic activity.
Onset: 20-60 min (immediate- or extended-release); 60-180 min (sustained-release); 60 min (TTS).
Duration: 3-5 hr (immediate-release); 6-12 hr (extended-release); 2-6 hr (sustained-release); 11-12 hr (TTS).
Absorption: Readily absorbed from the GI tract (oral). Food enhances rate of absorption. Time to peak plasma concentration: Approx 2 hr (immediate-release).
Distribution: Distributed into breast milk. Plasma protein binding: 10-33%.
Metabolism: Undergoes extensive first-pass metabolism. Extensively metabolised via de-esterification by carboxylesterase CES1A1 to ritanilic acid.
Excretion: Via urine (90% as metabolites and unchanged drug) and faeces (small amounts). Plasma elimination half-life: Approx 2 hr (oral); approx. 3-4 hr (TTS).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Methylphenidate, CID=4158, (accessed on Jan. 22, 2020)

Bảo quản
Store between 20-25°C. Protect from light and moisture.
Phân loại MIMS
Thuốc TKTW khác & thuốc trị rối loạn tăng động giảm chú ý
Phân loại ATC
N06BA04 - methylphenidate ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.
Tài liệu tham khảo
Anon. Methylphenidate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 13/06/2016.

Buckingham R (ed). Methylphenidate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 13/06/2016.

Daytrana Patch (Noven Therapeutics, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 13/06/2016.

Joint Formulary Committee. Methylphenidate Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 13/06/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Methylphenidate Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 13/06/2016.

Methylphenidate Capsule, Extended Release (Sandoz Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 13/06/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Methylphenidate từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in